-
2023-503766-24-00
11
2026-05-26
Moderate to Severe Plaque Psoriasis
-
2025-524265-24-00
5
2026-05-21
Dyslipidemia at High to Very High Cardiovascular Risk
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2025-523975-48-00
5
2026-05-08
Obesity
-
2025-524514-28-00
4
2026-05-06
Type 2 Diabetes Mellitus
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-520771-59-00
4
2026-02-03
Atopic Dermatitis
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2024-520206-19-00
5
2025-12-02
Hyperuricemia associated with gout.
-
2024-516520-34-00
3
2025-11-17
Rheumatoid Arthritis
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-515682-34-00
5
2025-10-06
Chronic migraine
-
2024-515715-22-00
5
2025-10-06
Episodic migraine
-
2025-520499-24-00
5
2025-10-01
Moderate to Severe Platysma Prominence
-
2024-519152-82-00
5
2025-09-03
Relapsed/Refractory Follicular Lymphoma
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML